How will the reported $400,000 revenue for Q2 compare to analysts' expectations and prior quarters?

RenovoRx’s disclosure that Q2 2025 revenue topped $400 k is modest in absolute terms but, for a micro‑cap oncology‑device company, the key narrative is the growth relative to both the prior quarter and the consensus outlook. The press release does not supply the exact figure for Q1 2025 or Q2 2024, but the phrase “over $400 k” and the explicit mention of “commercial revenue growth” suggest that the company is seeing a step‑up from the prior period—likely a double‑digit increase, given the emphasis on “growth”. Analysts covering RNXT have historically expected “low‑hundreds‑of‑thousands” range revenue for the early‑stage commercial segment, so the headline “over $400 k” is likely a beat of the low‑end consensus and could be interpreted as a modest upside surprise.

From a trading standpoint, the revenue beat combined with a positive independent data monitoring committee (IDMC) recommendation for the pivotal TIGeR‑PaC Phase III trial adds a catalyst that may outweigh the modest revenue figure. On the technical side, RNXT has been trading in a tight range around the $2–$3 price band, with the 20‑day EMA just below the 50‑day EMA and modest volume on the day of the release. A short‑term bullish bias is justified if the stock breaks above the recent high (~$3.20) on higher volume, as the positive trial signal could accelerate a breakout. Conversely, a failure to sustain the breakout could see the stock retest the $2.50 support. Actionable insight: consider a long‑call or buy‑on‑breakout position targeting $3.50‑$4.00 if the price breaches $3.20 with confirming volume; set a stop just below the 20‑day EMA (~$2.70) to protect against a rapid pullback if the trial data later underperform expectations.